Orchestra BioMed Holdings (OBIO) Research & Development (2022 - 2026)

Orchestra BioMed Holdings (OBIO) has 5 years of Research & Development data on file, last reported at $15.8 million in Q1 2026.

• On a quarterly basis, Research & Development rose 17.05% year-over-year to $15.8 million in Q1 2026; TTM through Mar 2026 was $60.5 million, a 28.21% increase from a year earlier, with the FY2025 full-year figure at $58.2 million, up 35.93% from the prior year.
• Research & Development for Q1 2026 stood at $15.8 million, down from $16.8 million in the prior quarter.
• Over the last five years, Research & Development for OBIO reached as high as $16.8 million in Q4 2025 and fell as low as $3.5 million in Q1 2022.
• Historically, Research & Development has averaged $10.1 million across 5 years, with a median of $9.1 million in 2024.
• Across the five-year window, Research & Development soared 137.59% in 2023 and increased 10.39% in 2024, its largest moves.
• Year by year, Research & Development stood at $7.5 million in 2022, then grew by 12.83% to $8.5 million in 2023, then grew by 28.9% to $11.0 million in 2024, then soared by 53.34% to $16.8 million in 2025, then decreased by 6.19% to $15.8 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $15.8 million in Q1 2026, $16.8 million in Q4 2025, and $14.0 million in Q3 2025.